Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Computational and stastistical methods help us understand evolution as well as genetic disease. Looking at our genomes opens up clinical possibilities, for example in cancer, allowing more genes to be looked at - more quickly and more cheaply, wich can impact prognosis and treatment selection.

Q: Can you tell us a bit about the basic research question that you are interested in?

GL: My group is involved in method development. Broadly, if I have to summarise it in one sentence: we are developing computational and statistical methods to analyse DNA sequence data, with the aim of improving our understanding of evolution and genetic disease.

Q: What is the relationship between disease and evolution?

A: That is a very good question because evolution is very fundamental and doesn't immediately have an impact on disease. However, if you look at a genome from an evolutionary perspective and you compare our genome with that of other animals, you see that certain bits evolve very quickly and certain bits do not change very much. Those bits that do not change very much are very likely to have a biological function. So when interpreting the mutations you find in a patient, it is very helpful to know which bits are likely to have an impact on our biology and which don't. In that way they help us interpret the mutations that humans carry.

Q: What kind of methods do you use to answer these questions?

GL: Very broadly we are using two categories of methods. One is statistical methods and the reason for these is that the data volumes are so big: we see so much signal, and of course, there is noise in this signal. Statistical methods are really crucial to identify which things we see are real - and which things are just there because you have so much data that everything will happen once, so to speak.

The second category of methods is computational, again because the data volumes are so huge we need to be very careful about the kinds of processes we let loose on the data, because if you don't think about it, we will be waiting forever and there are certain situations where that is just not acceptable.

Q: What are the most important lines of research that have emerged in the last 5-10 years?

GL: From my perspective the field of genetics has really undergone an evolution in the last 15 years. And just to give an example, it is only about 15 years ago that the human genome was sequenced for the first time, that we had a first look at the DNA that constitutes our biology. That was the end point of an effort that took 10 years and about 3 billion dollars, so there was a huge effort, it was a real milestone. Only 15 years later, currently I could have my genome sequenced for $1000 in 24 hours; that is like 3000 times faster and 3 million times cheaper and that is really tremendous. It opens up a lot of clinical possibilities as well. I think is for me the most interesting aspect of the field: it is really technology driven.

Q: Why does this line of research matter and why should we fund it?

GL: These possibilities of looking at our genome open up clinical possibilities, particularly for genetic disease, and one very good example of a genetic disease is cancer. Cancer is really a disease of our genomes: certain cells in our body that do not have the right, have changes in the genome and this effectively causes cancer. This technology allows us for the first time to actually have a detailed look at the genome of that cancer and try to figure out what is driving its transformation, and also to try to use the technology to develop early diagnostics which might help. And finally we hope that our understanding of the disease will also lead to new ways of treating this cancer. So that is a good example of why there is a huge amount of interest of using this technology to help drive the research in cancer forward.

Q: How does your work fit in translational medicine within the department?

GL: There are certain aspects of my work which are quite long term and will take a certain amount of time - years, for it to have an impact on clinical practise. But a number of the computational tools we have developed are already being used in clinical practise. One example is a collaboration with Professor Nazneen Rahman at the Institute of Cancer Research: in collaboration with her we have developed a computational pipeline that allows her to screen cancer patients for cancer predisposing mutations. There was a test already in existence but our new pipeline allows her to look at many more genes, much more quickly and also much more cheaply so it is better on all those three counts. Not only does it make the whole process smoother and cheaper, but it actually has an impact on the prognosis of certain patients and in their treatment, so that is really exciting and a good example of a real impact on clinical practise.

Gerton Lunter

Computational genomics

Professor Gerton Lunter is interested in investigating the processes of evolution and biology using computational methods.
His focus is on sequencing data; Professor Lunter develops methods to investigate evolutionary questions in population genetics.

More podcasts related to Genetics

Anna Gloyn: Genetics and Diabetes

Predictions suggest that by 2030, 366 million people worldwide will be affected by diabetes, a disease which already uses 10% of the NHS budget. Continued breakthroughs in the area of genetics related to different types of diabetes enable better diagnosis and treatment for patients and identify novel pathways that can be targeted for therapeutic interventions.

Erika Mancini: Chromatin Remodelling

Chromatin plays an important role in the regulation of gene expression. The movement of nucleosomes, packing and unpacking DNA, is governed by chromatin remodelling ATPases. Malfunctions in the regulation of chromatin structure often leads to complex multi-system diseases and cancer, notably leukemia.

Diabetes and Genomics by Mark McCarthy

Diabetes and obesity are both major challenges for global healthcare, with the social, health and economic costs over the next fifty years being in the ‘trillions’ of dollars. Genetics is one of the more important tools for developing a systematic understanding of the disease and how best to treat it in different patients.

Silvia Paracchini: Dyslexia and Genetics

Dyslexia is an impairment in learning to read that affects up to 10% of children; it can have profound effects on an individual life. Dyslexia has an important genetic component; candidate genes control important stages during foetal brain development. Understanding the biology of dyslexia could help us design more effective diagnostic criteria and treatment plans.

Claire Palles: Gastrointestinal cancers

The gastrointestinal track is responsible for more cancers than any other system. A condition called Barrett's oesophagus, characterised by a change in the cells lining the oesophagus, can lead to oesophageal adenocarcinoma. Only few people with Barrett's oesophagus will go on to develop cancer, and genome sequencing studies aim to identify genetic risk factors and therefore better target high-risk patients.

Antonio Velayos-Baeza: Rare neurological disorders

ChAc is a rare progressive neurological disorder caused by mutations in a very complex gene. A better understanding of the biology underlying this disease helps develop better diagnostic tools, and opens up the possibility of discovering targets for possible future treatments.

Zamin Iqbal: Computation and genetics

Resistance to drugs in bacteria can be aquired by swapping genes between individual bacteria. Computer programs developed by Dr Iqbal enable doctors to predict which antibiotics will be met with drug resistance, enabling the selection of the right drug. His work also enables the tracking of an infection from patient to patient, as well as the tracking of the spread of an infection within a hospital.

Catherine Green: DNA replication and Cancer

The process of DNA replication is complex, and mistakes can lead to genome instability. Surveillance systems are not always successful which results in mutations that have the potential to inactivate genes or change their activity. This can lead to cancer, and many chemotherapeutic drugs are designed to disrupt DNA replication. A better understanding of these mechanisms can help us develop new drugs with reduced side effects.

Christopher Yau: Big Data

Over the past decade, data-driven science has produced enormous sets of data. The convergence of statistics and computer science, in the field known as machine learning, provide the means to understand these large datasets. Ultimately, machine learning algorithms will be develop into clinical decision making support systems.

Peter Donnelly: Human Genetics

Professor Donnelly tries to understand the genetic basis of common human diseases. Information about the genetic variants can give us clues into the biology of the diseases. We can then use that information to develop new drugs, to find new drug targets and develop new therapies. Changes in clinical practice are already happening, and we expect genetics to play an important role in translational medicine over the next ten or twenty years.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.